DOCSLIB.ORG

Combined Occlusal and Pharmacological Therapy in the Treatment of Temporo-Mandibular Disorders

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Combined Occlusal and Pharmacological Therapy in the Treatment of Temporo-Mandibular Disorders Eur opean Rev iew for Med ical and Pharmacol ogical Sci ences 2011; 15: 1296-1300 Combined occlusal and pharmacological therapy in the treatment of temporo-mandibular disorders F. INCHINGOLO 2, M. TATULLO 3,4 , M. MARRELLI 3, A.M. INCHINGOLO 6, A. TARULLO 5, A.D. INCHINGOLO 5, G. DIPALMA 3, S. PODO BRUNETTI 1, A. TARULLO 1, R. CAGIANO 1 1Department of Biomedical Sciences and Human Oncology, Toxicology Unit, University of Bari, Bari (Italy) 2Department of Dental Sciences and Surgery, University of Bari, Bari (Italy) 3Department of Maxillofacial Surgery, Calabrodental, Crotone (Italy) 4Department of Medical Biochemistry, Medical Biology and Physics, University of Bari, Bari (Italy) 5Dental School, School of Medicine, University of Bari, Bari (Italy) 6Dental School, School of Medicine, University of Milan, Milan (Italy) Abstract. – Objective: Aim of the present be guessed by the wide range of terms used over work is to assess the effectiveness of a scientif - the years to point out the alterations of the masti - ic protocol built up to relieve pain in chronic catory system, creating further confusion in a temporo-mandibular disorders (TMD) using field characterized by an interesting and wide Michigan splint together with a pharmacological multiplicity of nuances 1,2 . Nowadays, the term therapy compared to the traditional occlusal Temporo-Mandibular Disorder (TMD) is general - thePratpiyenbtys: Michigan splint alone. 35 adult patients, with signs and symp - ly used. It includes all the alterations connected to toms of TMD lasting more than 6 months, were en - the function of the entire masticatory system. Re - rolled into this study and divided into two groups: cently, epidemiological studies indicate that the first receiving occlusal therapy by Michigan around 60% of the total population shows splint and pharmacological therapy with Delo - myoarthropathy symptoms. In particular, the razepam and Thiocolchicoside, while the second re - ceiving occlusal therapy by Michigan splint and prevalence of symptoms seems to be around 59%, “placebo” administration. The comparisons be - while the prevalence of signs reaches almost the tween the two experimental groups were assessed 80% of the total population. This high prevalence usiRngesau5ltsstepasnvdisuCaol-nancalulosgiuoenssc: ale (V.A.S.). highlights a clear picture of their wide spread dif - The outcomes fusion, although this is certainly due to the inclu - from the experimental groups were statistically sion, in many scientific works, of signs and compared resulting significantly different with symptoms of little importance 3-11 . The Michigan an improvement or disappearance of signs and symptoms in the treated group with respect to splint is a removable appliance frequently used in the placebo group at 12 and 1p8 months from the the treatment of patients with TMD and related beginning of the experiment ( < 0.001). diseases, such as tensive headache. Key Words: The aim of the present study is to assess the effectiveness of a new protocol built up to relieve TMDs, Combined occlusal and pharmacological ther - pain with pharmacological treatment of chronic apy, Michigan splint, Delorazepam, Thiocolchicoside. TMD, compared to the traditional occlusal thera - py protocol by Michigan splint without effective pharmacological therapy. Introduction Materials and Methods The term myoarthropathy of the masticatory system refers to a large number of pathologic 35 patients were enrolled in this study, 21 conditions affecting the masticatory musculature women (40 ± 10 years old) and 14 men (30 ± 5 and/or the Temporo-Mandibular Articulation years old), who were diagnosed for TMDs; clin - (TMA). The complexity of this subject matter can ical criteria were palpation-related pain and Corresponding Author: Raffaele Cagiano, MD; e-mail: [email protected] 1296 Combined occlusal and pharmacological therapy in the treatment of temporo-mandibular disorders cy of its chloride ion channel resulting in the therapeutic benzodiazepines actions 13 . Thiocolchicoside Thiocolchicoside is a muscle relaxant with an - ti-inflammatory and analgesic effects. It acts as a competitive GABA-A receptor antagonist and al - so inhibits glycine receptors with similar potency and nicotinic acetylcholine receptors to a much lesser extent. It has powerful convulsant activity and should not be used in seizure-prone individu - als. It is a natural glucoside of colchicum without curare-like effects. Thiocolchicoside does not al - terate voluntary motility and does not interfere with respiratory muscles. It has no valuable ef - fects on the cardiovascular system. Instrumental examinations were performed by panoramic X-ray (OPT) and magnetic resonance of the TMA. A visual-analogue scale (V.A.S.) 14 was used in order to evaluate the intensity pain referred by patients consequent to palpation (Table I). The first group (treated group = 19 patients) re - ceived an occlusal therapy with “ Michigan splint ” (Figure 3) and pharmacological therapy with “de - lorazepam drops” and “thiocolchicoside tablets”. Figure 1. Palpation of the masticatory muscles. The second group (placebo group – 16 patients) received occlusal therapy with “Michigan splint” and “Placebo” administration: tablets and drops, clicking or limited mouth opening. The clinical diagnosis of TMDs was based on a patient symptom questionnaire including intra -oral and extra -oral muscle examination (Figure 1). All patients were examined by the same investiga - tor in order to avoid any kind of bias. Further - more, all subjects signed an informed consent form confirming their voluntary participation in this study. During the objective exams, all pa - tients referred spontaneous and palpation-relat - ed pain (Figure 2). Used Drugs Delorazepam Delorazepam (Chlordemethyldiazepam) is a long acting benzodiazepine with anxiolytic, hyp - noinducing, myorelaxant and anticonvulsant ac - tivities. It is considered a short-acting benzodi - azepine drug which exerts both therapeutic and adverse effects linking with high affinity to GABA A receptor sites in the central nervous sys - Figure 2. 12 Magnetic Resonance of the TMA of a patient be - tem enhancing the effects of GABA at the fore our therapy. Anterior subdislocation of the right TMA’s GABA A receptor increasing the opening frequen - meniscus. 1297 F. Inchingolo, M. Tatullo, M. Marrelli, A.M. Inchingolo, A. Tarullo, A.D. Inchingolo, et al. Table I. Visual-analogue scale. The greatest No Mild Troublesome imaginable pain pain pain Intense pain pain 001212 33445 5 6677 89 8 9 10 prepared by a pharmacist, were similar to those and Wednesday on the 2nd week, Sunday, Tues - used in the first group, but without the active drugs. day and Friday on the 3rd week, Sunday, Tues - Patients were asked to express their pain inten - day Thursday and Saturday on the 4th week and sity marking a point on a straight line, whose left wearing it only on Sunday for the next 2 weeks. limit was 0 (corresponding to absence of pain ) The remaining period of time (6 weeks) was con - and right limit was 10 (corresponding to the sidered necessary for a full wash-out from phar - greatest imaginable pain ). The VAS data were macological treatment. collected at T 0 and after 6 (T1), 12 ( T2) and 18 Statistical Analysis months (T max ) from the beginning of treatment . Data collected from the experimental group V.A.S. data were statistically evaluated using treated with “Michigan splint” and “delorazepam Unpaired t-test . Analysis of variances was fur - and thiocolchicoside” were compared with data ther performed with a nonparametric test. p value collected from experimental group treated with was statistically significant when < 0.05. occlusal therapy and “Michigan splint” alone. Furthermore, regarding the occlusal therapy, pa - Results tients were asked to wear their splint overnight along the first 12 months, positioned on superior arch. About the pharmacological therapy, the daily Comparisons between VAS values of the two dose used were: experimental groups (Unpaired t-test) before to • Delorazepam drops, 1 mg/day (12 drops/day) begin the treatment, gave not significant results along 12 months, decreasing 1 drop every month (p=0.2990) (two-tailed p=0.6479, t=0.461; up to 1 drop/day during the whole 12 th month ; df=33) allowing us to proceed . • Thiocolchicoside, 1 tablet 4 mg/12 hours along VAS values of the two experimental groups 12 months . were further compared: Soon after the 12 months treatment, all pa - tients were asked to gradually discard their splint At 6 months from the beginning of the treatment, the not wearing it on Sunday in the 1st week, Sunday comparisons between VAS values of the two experi - mental groups gave the following results: (two-tailed p < 0.0088; t=2.785; df=33); F test comparing vari - ances gave no significant results (F=1.739; DFn=18; Dfd=15; n.s.) ; At 12 months from the beginning of the treat - ment, VAS data comparisons gave significant results (two tailed p < 0.0001 ; t=7.728; df=33); F test comparing variances (F=3.343; DFn=18; Dfd=15; p < 0.0112); At 18 months from the beginning of the treat - ment , VAS data comparison also gave signifi - cant results (two-tailed p < 0.0001); t=9.041; Figure 3. df=33). F test comparing variances (F= 4.754; Michigan splint. DFn=18; Dfd=15; p < 0.0019). 1298 Combined occlusal and pharmacological therapy in the treatment of temporo-mandibular disorders Some patients regularly using the Michigan occlusal problems, they were considered the only splint (28 patients=80%) declared
Load more

Recommended publications
  • Reversal of Neuromuscular Bl.Pdf
    JosephJoseph F.F. Answine,Answine, MDMD Staff Anesthesiologist Pinnacle Health Hospitals Harrisburg, PA Clinical Associate Professor of Anesthesiology Pennsylvania State University Hospital ReversalReversal ofof NeuromuscularNeuromuscular BlockadeBlockade DefiniDefinitionstions z ED95 - dose required to produce 95% suppression of the first twitch response. z 2xED95 – the ED95 multiplied by 2 / commonly used as the standard intubating dose for a NMBA. z T1 and T4 – first and fourth twitch heights (usually given as a % of the original twitch height). z Onset Time – end of injection of the NMBA to 95% T1 suppression. z Recovery Time – time from induction to 25% recovery of T1 (NMBAs are readily reversed with acetylcholinesterase inhibitors at this point). z Recovery Index – time from 25% to 75% T1. PharmacokineticsPharmacokinetics andand PharmacodynamicsPharmacodynamics z What is Pharmacokinetics? z The process by which a drug is absorbed, distributed, metabolized and eliminated by the body. z What is Pharmacodynamics? z The study of the action or effects of a drug on living organisms. Or, it is the study of the biochemical and physiological effects of drugs. For example; rocuronium reversibly binds to the post synaptic endplate, thereby, inhibiting the binding of acetylcholine. StructuralStructural ClassesClasses ofof NondepolarizingNondepolarizing RelaxantsRelaxants z Steroids: rocuronium bromide, vecuronium bromide, pancuronium bromide, pipecuronium bromide. z Benzylisoquinoliniums: atracurium besylate, mivacurium chloride, doxacurium chloride, cisatracurium besylate z Isoquinolones: curare, metocurine OnsetOnset ofof paralysisparalysis isis affectedaffected by:by: z Dose (relative to ED95) z Potency (number of molecules) z KEO (plasma equilibrium constant - chemistry/blood flow) — determined by factors that modify access to the neuromuscular junction such as cardiac output, distance of the muscle from the heart, and muscle blood flow (pharmacokinetic variables).
    [Show full text]
  • Summary of Product Characteristics
    Health Products Regulatory Authority Summary of Product Characteristics 1 NAME OF THE MEDICINAL PRODUCT Murexal 10 mg/mL solution for injection in pre-filled syringe 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each mL of solution for injection contains 10 mg of suxamethonium chloride anhydrous (as 11 mg of suxamethonium chloride dihydrate). Each 10 ml pre-filled syringe contains 100 mg of suxamethonium chloride anhydrous (as 110 mg of suxamethonium chloride dihydrate). Excipient with known effect: Each ml of solution for injection contains 2.79 mg equivalent to 0.12 mmol of sodium. Each 10 ml pre-filled syringe contains 27.9 mg equivalent to 1.2 mmol of sodium. For the full list of excipients, see section 6.1. 3 PHARMACEUTICAL FORM Solution for injection (injection). Clear and colourless solution. pH: 3.0 – 4.5 Osmolality: 250-350 mOsm/Kg 4 CLINICAL PARTICULARS 4.1 Therapeutic Indications Murexal is indicated as a muscle relaxant to facilitate endotracheal intubation during induction of general anaesthesia or emergency situations, in adults and paediatric population above 12 years of age. 4.2 Posology and method of administration Suxamethonium should be administered only by or under close supervision of an experienced clinician (anaesthesist, intensivist, emergency physician) familiar with its action, characteristics and hazards, who is skilled in the management of intubation and artificial respiration and only where there are adequate facilities for immediate endotracheal intubation with administration of oxygen by intermittent positive pressure ventilation. It is given intravenously after anaesthesia has been induced and should not be administered to the conscious patient. Posology Adults To achieve endotracheal intubation, suxamethonium chloride is usually administered by bolus intravenous injection in a dose of 1 mg/kg body weight.
    [Show full text]
  • Clinical Pharmacokinetics and Pharmacodynamics CONCEPTS and APPLICATIONS 18048 FM.Qxd 11/11/09 4:31 PM Page Iii
    18048_FM.qxd 11/11/09 4:31 PM Page i Clinical Pharmacokinetics and Pharmacodynamics CONCEPTS AND APPLICATIONS 18048_FM.qxd 11/11/09 4:31 PM Page iii FOURTH EDITION Clinical Pharmacokinetics and Pharmacodynamics Concepts and Applications Malcolm Rowland, DSc, PhD Thomas N. Tozer, PharmD, PhD Professor Emeritus Professor Emeritus School of Pharmacy and School of Pharmacy and Pharmaceutical Sciences Pharmaceutical Sciences University of Manchester University of California, San Francisco Manchester, United Kingdom Adjunct Professor of Pharmacology Skaggs School of Pharmacy and Pharmaceutical Sciences University of California San Diego With Online Simulations by Hartmut Derendorf, PhD Distinguished Professor Guenther Hochhaus, PhD Associate Professor Department of Pharmaceutics University of Florida Gainesville, Florida 18048_FM.qxd 11/11/09 4:31 PM Page iv Acquisitions Editor: David B. Troy Product Manager: Matt Hauber Marketing Manager: Allison Powell Designer: Doug Smock Compositor: Maryland Composition Inc./ASI Fourth Edition Copyright © 2011 Lippincott Williams & Wilkins, a Wolters Kluwer business 351 West Camden Street 530 Walnut Street Baltimore, MD 21201 Philadelphia, PA 19106 Printed in China All rights reserved. This book is protected by copyright. No part of this book may be reproduced or transmitted in any form or by any means, including as photocopies or scanned-in or other electronic copies, or utilized by any information storage and retrieval system without written permission from the copyright owner, except for brief quotations embodied in critical articles and reviews. Materials appearing in this book prepared by individuals as part of their official duties as U.S. government em- ployees are not covered by the above-mentioned copyright. To request permission, please contact Lippincott Williams & Wilkins at 530 Walnut Street, Philadelphia, PA 19106, via email at permis- [email protected], or via website at lww.com (products and services).
    [Show full text]
  • Drug Administration in Cataract Surgery* by L
    Br J Ophthalmol: first published as 10.1136/bjo.43.5.302 on 1 May 1959. Downloaded from Brit. J. Ophthal. (1959) 43, 302. DRUG ADMINISTRATION IN CATARACT SURGERY* BY L. P. AGARWAL, R. B. L. GUPTA, AND S. R. K. MALIK From the Department of Ophthalmology, All-India Institute ofMedical Sciences, New Delhi, India THE problem of cataract surgery in India is immense. Great economic loss is caused by improper and inadequate surgery, and through lack of education, the cooperation of the patient is not all one would like it to be. Vitreous prolapse occurs in 7 to 9 per cent. of routinely-sedated patients, and iris prolapse in about 4 per cent., where a peripheral iridectomy has been done and a stitch applied. The visual results are often poor and ophthalmic surgeons tend to lay the blame on the patient. With all the means at our disposal to-day, however, this is rather unfair, and we have managed to obtain better relaxation by operating under curare akinesia. We have been fortunate in not meeting many complications (Agarwal and Mathur, 1952; Agarwal, 1953), but the use of curare alone in the doses usually given is not without risk, nor does it eliminate post-opera- tive hazards. Chlorpromazine (Agarwal, Gupta, and Malik, 1957) has also given encouraging results when used for sedation, and both drugs lowered the intra-ocular pressure to safe limits even when it was high initially. We have also had some success with acetazoleamide used before and after http://bjo.bmj.com/ operation (Agarwal, and Malik, 1957; Agarwal, Sharma, and Malik, 1955).
    [Show full text]
  • Practical Guidance for the Evaluation and Management of Drug Hypersensitivity: Specific Drugs
    Specific Drugs Practical Guidance for the Evaluation and Management of Drug Hypersensitivity: Specific Drugs Chief Editors: Ana Dioun Broyles, MD, Aleena Banerji, MD, and Mariana Castells, MD, PhD Ana Dioun Broyles, MDa, Aleena Banerji, MDb, Sara Barmettler, MDc, Catherine M. Biggs, MDd, Kimberly Blumenthal, MDe, Patrick J. Brennan, MD, PhDf, Rebecca G. Breslow, MDg, Knut Brockow, MDh, Kathleen M. Buchheit, MDi, Katherine N. Cahill, MDj, Josefina Cernadas, MD, iPhDk, Anca Mirela Chiriac, MDl, Elena Crestani, MD, MSm, Pascal Demoly, MD, PhDn, Pascale Dewachter, MD, PhDo, Meredith Dilley, MDp, Jocelyn R. Farmer, MD, PhDq, Dinah Foer, MDr, Ari J. Fried, MDs, Sarah L. Garon, MDt, Matthew P. Giannetti, MDu, David L. Hepner, MD, MPHv, David I. Hong, MDw, Joyce T. Hsu, MDx, Parul H. Kothari, MDy, Timothy Kyin, MDz, Timothy Lax, MDaa, Min Jung Lee, MDbb, Kathleen Lee-Sarwar, MD, MScc, Anne Liu, MDdd, Stephanie Logsdon, MDee, Margee Louisias, MD, MPHff, Andrew MacGinnitie, MD, PhDgg, Michelle Maciag, MDhh, Samantha Minnicozzi, MDii, Allison E. Norton, MDjj, Iris M. Otani, MDkk, Miguel Park, MDll, Sarita Patil, MDmm, Elizabeth J. Phillips, MDnn, Matthieu Picard, MDoo, Craig D. Platt, MD, PhDpp, Rima Rachid, MDqq, Tito Rodriguez, MDrr, Antonino Romano, MDss, Cosby A. Stone, Jr., MD, MPHtt, Maria Jose Torres, MD, PhDuu, Miriam Verdú,MDvv, Alberta L. Wang, MDww, Paige Wickner, MDxx, Anna R. Wolfson, MDyy, Johnson T. Wong, MDzz, Christina Yee, MD, PhDaaa, Joseph Zhou, MD, PhDbbb, and Mariana Castells, MD, PhDccc Boston, Mass; Vancouver and Montreal,
    [Show full text]
  • Anticholinergic Syndrome 23 William J
    Anticholinergic Syndrome 23 William J. Boroughf Contents The anticholinergic syndrome is common and Overview and Incidence ............................ 521 may result from exposures to many drugs or nat- ural substances (Table 1). Anticholinergic effects History ............................................... 521 are desired or intended effects for certain drugs Pathophysiology .................................... 522 (i.e., antispasmodics, mydriatics, and belladonna Toxic Mechanism .................................... 523 alkaloids) and are undesired or side-effects for Clinical Presentations and Life-Threatening other drugs (i.e., antihistamines, antidepressants, Complications ....................................... 525 antipsychotics, and antiparkinsonians). Both pre- Routes of Exposure .................................. 526 Intention or Cause of Exposures ..................... 526 scription and over-the-counter drugs may have Range of Toxicity .................................... 527 anticholinergic effects. Combined use of more Organ System Effects ................................ 527 than one drug with anticholinergic effects Diagnosis ............................................ 529 increases the risk of anticholinergic toxicity. The Laboratory Tests ..................................... 529 anticholinergic syndrome, also called the anticho- Differential Diagnosis . ............................. 530 linergic toxidrome, has peripheral and central Diagnostic Studies ................................... 531 manifestations. The more
    [Show full text]
  • Chapter 13 – Pharmacology of Muscle Relaxants and Their Antagonists Mohamed Naguib, Cynthia A
    Chapter 13 – Pharmacology of Muscle Relaxants and Their Antagonists Mohamed Naguib, Cynthia A. Lien HISTORY AND CLINICAL USE In 1942 Griffith and Johnson[1] suggested that d-tubocurarine (dTc) is a safe drug to use during surgery to provide skeletal muscle relaxation. One year later, Cullen[2] described its use in 131 patients who had received general anesthesia for their surgery. In 1954, Beecher and Todd[3] reported a sixfold increase in mortality in patients receiving dTc versus those who had not received a relaxant. The increased mortality was due to a general lack of understanding of the pharmacology of neuromuscular blockers and their antagonism. The impact of residual neuromuscular blockade postoperatively was not appreciated, guidelines for monitoring muscle strength had not been established, and the importance of pharmacologically antagonizing residual blockade was not understood. Since then, the understanding of neuromuscular blocker pharmacology has improved, and relaxants have become an important component of many anesthetics and have facilitated the growth of surgery into new areas with the use of innovative techniques.[4] Succinylcholine, introduced by Thesleff[5] and by Foldes and colleagues in 1952,[4] changed anesthetic practice drastically. Its rapid onset of effect and ultrashort duration of action allowed for rapid tracheal intubation. In 1967, Baird and Reid first reported on clinical administration of the synthetic aminosteroid pancuronium.[6] Though similar to dTc, in terms of its duration of action, this compound had an improved cardiovascular side effect profile. It lacked ganglionic-blocking and histamine-releasing properties and was mildly vagolytic. The resulting increases in heart rate and blood pressure were considered significant improvements over its predecessors.
    [Show full text]
  • Curare - Wikipedia, the Free Encyclopedia 2/25/12 5:48 PM Curare from Wikipedia, the Free Encyclopedia
    Curare - Wikipedia, the free encyclopedia 2/25/12 5:48 PM Curare From Wikipedia, the free encyclopedia Curare /kjuːˈrɑːriː/[1] is a common name for various arrow poisons originating from South America. The three main types of curare are: tubocurare (also known as tube or bamboo curare, because of its packing into hollow bamboo tubes; main toxin is D-tubocurarine). It is a mono-quaternary alkaloid, an isoquinoline derivative. calebas curare (also called "gourd curare" by older British classifications, being packed into hollow gourds; main toxins are alloferine and toxiferine) pot curare (packed in terra cotta pots; main toxins are protocurarine, protocurine, and protocuridine). Of these three types, some formulas belonging to the calebas curare are the most toxic, relative to their LD50 values. Strychnos toxifera by Koehler 1887 Contents 1 History 2 Pharmacological properties 3 Anesthesia 4 Plants from which primary components of curare can be extracted 5 Names 6 Notes 7 References 8 External links History Curare was used as a paralyzing poison by South American indigenous people. The prey was shot by arrows or blowgun darts dipped in curare, leading to asphyxiation owing to the inability of the http://en.wikipedia.org/wiki/Curare Page 1 of 5 Curare - Wikipedia, the free encyclopedia 2/25/12 5:48 PM victim's respiratory muscles to contract. The word curare is derived from wurari, from the Carib language of the Macusi Indians of Guyana.[2] In 1596 Sir Walter Raleigh mentioned the arrow poison in his book Discovery of the Large, Rich, and
    [Show full text]
  • The Selection and Use of Essential Medicines
    This report contains the collective views of an international group of experts and does not necessarily represent the decisions or the stated policy of the World Health Organization WHO Technical Report Series 933 THE SELECTION AND USE OF ESSENTIAL MEDICINES Report of the WHO Expert Committee, 2005 (including the 14th Model List of Essential Medicines) World Health Organization Geneva 2006 i WHO Library Cataloguing-in-Publication Data WHO Expert Committee on the Selection and Use of Essential Medicines (14th : 2005: Geneva, Switzerland) The selection and use of essential medicines : report of the WHO Expert Committee, 2005 : (including the 14th model list of essential medicines). (WHO technical report series ; 933) 1.Essential drugs — standards 2.Formularies — standards 3.Drug information services — organization and administration 4.Drug utilization 5. Pharmaceutical preparations — classification 6.Guidelines I.Title II.Title: 14th model list of essential medicines III.Series. ISBN 92 4 120933 X (LC/NLM classification: QV 55) ISSN 0512-3054 © World Health Organization 2006 All rights reserved. Publications of the World Health Organization can be obtained from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 2476; fax: +41 22 791 4857; email: [email protected]). Requests for permission to reproduce or translate WHO publica- tions — whether for sale or for noncommercial distribution — should be addressed to WHO Press, at the above address (fax: +41 22 791 4806; email: [email protected]). The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries.
    [Show full text]
  • ICCB-L Plate (10 Mm / 3.33 Mm) ICCB-L Well Vendor ID Chemical Name
    ICCB-L Plate ICCB-L Therapeutic Absorption Protein FDA Additional info Additional info Vendor_ID Chemical_Name CAS number Therapeutic class Target type Target names (10 mM / 3.33 mM) Well effect tissue binding approved type detail Pharmacological 3712 / 3716 A03 Prestw-1 Azaguanine-8 134-58-7 Oncology Antineoplastic tool 3712 / 3716 A05 Prestw-2 Allantoin 97-59-6 Dermatology Antipsoriatic Carbonic 3712 / 3716 A07 Prestw-3 Acetazolamide 59-66-5 Metabolism Anticonvulsant Enzyme Carbonic anhydrase GI tract Yes anhydrase Potential Plasmatic New therapeutic 3712 / 3716 A09 Prestw-4 Metformin hydrochloride 1115-70-4 Endocrinology Anorectic GI tract Yes anticancer proteins use agent Chemical Plasmatic classification Quaternary 3712 / 3716 A11 Prestw-5 Atracurium besylate 64228-81-5 Neuromuscular Curarizing Yes proteins (according ATC ammonium code) 3712 / 3716 A13 Prestw-6 Isoflupredone acetate 338-98-7 Endocrinology Anti-inflammatory Therapeutic Amiloride-sensitive classification Potassium- 3712 / 3716 A15 Prestw-7 Amiloride hydrochloride dihydrate 17440-83-4 Metabolism Antihypertensive LGIC GI tract Yes sodium channel, ENaC (according ATC sparing agent code) 3712 / 3716 A17 Prestw-8 Amprolium hydrochloride 137-88-2 Infectiology Anticoccidial Veterinary use Poultry Therapeutic Solute carrier family 12 Plasmatic classification Low-ceiling 3712 / 3716 A19 Prestw-9 Hydrochlorothiazide 58-93-5 Metabolism Antihypertensive Carrier GI tract Yes member 3 proteins (according ATC diuretic code) Chemical classification 3712 / 3716 A21 Prestw-10 Sulfaguanidine
    [Show full text]
  • Newer Agents for the Anesthesiologist Paul R
    Henry Ford Hospital Medical Journal Volume 4 | Number 1 Article 3 3-1956 Newer Agents For The Anesthesiologist Paul R. Dumke Follow this and additional works at: https://scholarlycommons.henryford.com/hfhmedjournal Part of the Anesthesiology Commons, Life Sciences Commons, and the Public Health Commons Recommended Citation Dumke, Paul R. (1956) "Newer Agents For The Anesthesiologist," Henry Ford Hospital Medical Bulletin : Vol. 4 : No. 1 , 5-11. Available at: https://scholarlycommons.henryford.com/hfhmedjournal/vol4/iss1/3 This Article is brought to you for free and open access by Henry Ford Health System Scholarly Commons. It has been accepted for inclusion in Henry Ford Hospital Medical Journal by an authorized editor of Henry Ford Health System Scholarly Commons. For more information, please contact [email protected]. NEWER AGENTS FOR THE ANESTHESIOLOGIST* PAUL R. DUMKE, M.D.** At the time man began to look for agents which would produce pain relief and allow surgical procedures to be painless, he also became interested in methods of administering these agents. As we see our patients preoperatively most of them usually have two requests. First, they want to be "asleep" and second they want this "sleep" to be produced by an intravenous agent. Many specifically ask for pentothal. Some medical historians are already calling this present period "The Era of Intravenous Anesthesia."' We have been interested in finding the safest anesthetic agent for the patient; one which gives the surgeon the best operative conditions and still is pleasant for induction and has no after effects. To date, no one agent meets these criterion. Needless to say, the perfection of an anesthesia does not lie in a drug alone.
    [Show full text]
  • Medications and Myasthenia Gravis
    Medications and Myasthenia Gravis (A Reference for Health Care Professionals) Mehyar Mehrizi MD, Rodrigue F. Fontem MS, Tiffany R. Gearhart MS, and Robert M. Pascuzzi, MD Department of Neurology Indiana University School of Medicine Correspondence: Robert M. Pascuzzi, MD Chairman Department of Neurology 355 W. 16 th Street #4700 Indiana University School of Medicine Indianapolis, IN 46202 USA Telephone: 317/274-4455 E-mail: [email protected] Prepared for the Myasthenia Gravis Foundation of America August, 2012 1 Introduction Patients with myasthenia gravis (MG) or Lambert-Eaton syndrome (LES) may have worsening of symptoms upon exposure to a variety of medications. Underlying disorders of neuromuscular transmission may affect presynaptic release of acetylcholine (LES) or the postsynaptic muscle fiber membrane at the endplate (MG). Similarly, adverse drug effects can occur presynaptically or postsynaptically. In a patient with a reduced safety factor for neuromuscular transmission, exposure to a drug or clinical state which further reduces the efficiency of neuromuscular transmission can result in significant clinical weakness. Myasthenia Gravis The prototype NMJ disease is myasthenia gravis (MG). Familiarity with this disorder assists the clinician in recognizing others involving defective neuromuscular transmission. Furthermore, since MG is the most common of the junctional diseases, it represents the most common clinical setting in which use of specific drugs may lead to clinical worsening. Myasthenia gravis is an autoimmune disorder of neuromuscular transmission involving the production of autoantibodies directed against the nicotinic AChR. Receptor antibodies are detectable in the sera of 80-90% of patients with MG. The prevalence of MG is about 1 in 10-20,000.
    [Show full text]